Pay in 4 interest-free payments of $5.47 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Pulse Biosciences has announced treatment of the first two patients in a first-in-human feasibility study using its novel nanosecond pulsed field ablation (nsPFA) cardiac surgery system for cardiac tissue ablation in the treatment of atrial fibrillation (AF)
Evidence ranges from early laboratory work to clinical trials depending on the use the sections below cover the actual data and sources
Understanding why this plateau occursand how to optimise long-term outcomesis essential for patients and clinicians managing expectations and treatment strategies
US$ 28.25
US$ 24.78
US$ 27.73
US$ 25.68
US$ 28.42
US$ 28.04
